[Other] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).

SoadKassem Post time Half hour(s) ago | Show all posts |Read mode

This post will be closed automatically in 2026-08-07 09:45

Reward50points

Title: Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).

Authors: Lynn Huynh, Beilei Cai, Camara Sharperson, Dominique Lejeune, Mei Sheng Duh, and Michelle Kang Kim

J Clin Oncol 37, 105(2019)

Volume 37, Number 4_suppl

DOI: 10.1200/JCO.2019.37.4_suppl.105

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

SoadKassem Lv.2

Junior Member

post
reply
points
110

[Other] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET). Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).